Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Neuropace Inc(NPCE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NPCE
10/02/2026: NPCE (1-star) is currently NOT-A-BUY. Pass it for now.
Neuropace is a medical device company focused on the RNS System, an implantable technology for treating refractory focal epilepsy. Its primary strength lies in being the sole provider of closed-loop, brain-responsive neurostimulation, which has established it as a niche leader. The investment story centers on the company’s ability to scale through increased physician adoption and broader insurance coverage. Key risks include intense competition from larger medical device firms, the ongoing challenge of achieving profitability, and potential regulatory or clinical headwinds. This stock is best suited for growth-oriented investors who should monitor clinical progress and commercial sales growth as primary indicators of long-term success.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Neuropace offers significant potential growth through market penetration in the epilepsy space. |
| Momentum investor | Mixed fit | Momentum appeal depends on positive clinical and commercial milestones. |
| Value investor | Weak fit | The company is not currently profitable, making it a poor fit for traditional value metrics. |
| Dividend investor | Weak fit | No dividend is paid or expected in the near future. |
| Low-risk investor | Weak fit | High volatility and operational risks associated with a medical technology growth company. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap medical technology stocks often experience significant price swings based on news and market sentiment. |
| Valuation risk | Medium / high | Valuation relies heavily on future growth assumptions rather than current earnings. |
| Competition risk (Neuromodulation) | Medium / high | Incumbents like LivaNova and Medtronic have stronger financial resources. |
| Business quality | Medium | Proprietary technology is strong, but commercial scale is still developing. |
| Dividend income | Low / none | Investors should not expect any income from this stock. |
| Execution risk | Medium / high | Success depends on the consistent expansion of the sales force and clinical adoption. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 15.63% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 451.36M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 135.1K shares | Beta 1.95 | 52 Weeks Range 9.22 - 19.60 | Updated Date 10/02/2026 |
52 Weeks Range 9.22 - 19.60 | Updated Date 10/02/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Neuromodulation | Sale of RNS System hardware and ongoing recurring revenue from patient maintenance and support. | Revenue is generated by selling a specialized brain implant and supporting the long-term monitoring services needed for epilepsy patients. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 158.73 | Enterprise Value 507.35M | Price to Sales(TTM) 4.22 |
Enterprise Value 507.35M | Price to Sales(TTM) 4.22 | ||
Enterprise Value to Revenue 4.74 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 34.32M | Shares Floating 25.42M |
Shares Outstanding 34.32M | Shares Floating 25.42M | ||
Percent Insiders 4.46 | Percent Institutions 97.33 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Neuropace Inc
Exchange NASDAQ | Headquarters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 220 | Website https://www.neuropace.com |
Full time employees 220 | Website https://www.neuropace.com | ||
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.